JIMD Reports, Volume 26 pp 99-102 | Cite as
Screening for Attenuated Forms of Mucopolysaccharidoses in Patients with Osteoarticular Problems of Unknown Etiology
- 8 Citations
- 1 Mentions
- 517 Downloads
Abstract
Introduction: The mucopolysaccharidoses (MPS) are a group of 11 inborn errors of metabolism (IEM) which are part of the lysosomal storage diseases (LSDs). The MPS are multisystemic conditions that affect the entire body, with variations in the clinical presentation, having specific treatments available depending on the type of MPS. Nearly all MPS disorders compromise the osteoarticular system in different ways, and virtually all patients have abnormal urinary excretion of glycosaminoglycans (GAGs). MPS are rare diseases that are underdiagnosed due to health-care professionals’ lack of awareness, to poor access to screening and diagnostic methods, and to their extensive clinical heterogeneity. Attenuated forms may occur, which can make diagnosis of MPS even more difficult.
Methods: This study was conducted prospectively from March 2012 to January 2014 and included 55 patients at rheumatology and/or orthopedic services in Porto Alegre, Brazil. The screened patients presented with articular manifestations with no defined etiology. These patients were screened by quantitative and qualitative assessment of urinary GAGs.
Results and Discussion: Among the 55 cases investigated, one 15-year-old patient exhibited increased urinary GAG excretion; this patient was subsequently diagnosed with an attenuated form of MPS II, which was previously undetected.
Conclusion: Although the proportion of patients with MPS identified in the study sample was small (1/55), this study shows that these diseases are underdiagnosed and that systematic screening can help identify patients who may benefit from specific treatments already available for several MPS types.
Keywords
Glycosaminoglycans Hunter syndrome Mucopolysaccharidoses Osteoarticular disease Selective screeningNotes
Acknowledgments
The authors are grateful to CNPq (Brazilian National Council for Scientific and Technological Development); to FIPE/HCPA; to the Medical Genetics Service of Hospital de Clinicas de Porto Alegre, particularly its Laboratory of Inborn Errors of Metabolism (LEIM); and to the MPS Brazil Network.
References
- Cappelletti R, Del Rosso M, Chiarrugi VP (1979) A new electrophoretic method for complete separation of all known animal glycosaminoglycans in a monodimensional run. Anal Biochem 99:311–315CrossRefPubMedGoogle Scholar
- Cimaz R, Coppa GV, Koné-Paut I et al (2009) Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J 7:18CrossRefPubMedPubMedCentralGoogle Scholar
- De Jong JG, Wevers RA, Liebrand-van Sambeek R (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for Mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMedGoogle Scholar
- Giugliani R (2012) Mucopolysaccharidoses: from understanding to treatment, a century of discoveries. Genet Mol Biol 35:924–931CrossRefPubMedPubMedCentralGoogle Scholar
- Hendriksz C (2011) Improved diagnostic procedures in attenuated mucopolysaccharidosis. Br J Hosp Med (Lond) 72:91–95CrossRefGoogle Scholar
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254CrossRefPubMedGoogle Scholar
- Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421–3452Google Scholar
- Pennock CA (1976) A review and selection of simple laboratory methods used for the study of glycosaminoglycan and the diagnosis of the mucopolysaccharidoses. J Clin Path 29:111–123CrossRefPubMedPubMedCentralGoogle Scholar
- Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156CrossRefPubMedGoogle Scholar